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ABSTRACT
Objective: To assess the incremental cost and cost-
effectiveness of a restrictive versus a liberal red blood
cell transfusion threshold after cardiac surgery.
Design: A within-trial cost-effectiveness analysis with
a 3-month time horizon, based on a multicentre
superiority randomised controlled trial from the
perspective of the National Health Service (NHS) and
personal social services in the UK.
Setting: 17 specialist cardiac surgery centres in UK
NHS hospitals.
Participants: 2003 patients aged >16 years
undergoing non-emergency cardiac surgery with a
postoperative haemoglobin of <9 g/dL.
Interventions: Restrictive (transfuse if haemoglobin
<7.5 g/dL) or liberal (transfuse if haemoglobin <9 g/dL)
threshold during hospitalisation after surgery.
Main outcome measures: Health-related quality of
life measured using the EQ-5D-3L to calculate quality-
adjusted life years (QALYs).
Results: The total costs from surgery up to 3 months
were £17 945 and £18 127 in the restrictive and liberal
groups (mean difference is −£182, 95% CI −£1108 to
£744). The cost difference was largely attributable to the
difference in the cost of red blood cells. Mean QALYs to
3 months were 0.18 in both groups (restrictive minus
liberal difference is 0.0004, 95% CI −0.0037 to
0.0045). The point estimate for the base-case cost-
effectiveness analysis suggested that the restrictive
group was slightly more effective and slightly less costly
than the liberal group and, therefore, cost-effective.
However, there is great uncertainty around these results
partly due to the negligible differences in QALYs gained.
Conclusions: We conclude that there is no clear
difference in the cost-effectiveness of restrictive and
liberal thresholds for red blood cell transfusion after
cardiac surgery.
Trial registration number: ISRCTN70923932;
Results.
INTRODUCTION
Perioperative anaemia is common after
cardiac surgery and is associated with adverse
clinical outcomes, such as stroke, acute
kidney injury and death.1–3 Transfusion of
allogeneic red blood cells is a mainstay treat-
ment for acute anaemia and, on average,
over 50% of adult cardiac surgery patients
receive a perioperative blood transfusion.4 5
Cardiac surgery consumes a substantial pro-
portion of blood supplies; over 6% of all red
blood cell usage in the UK occurs in cardiac
surgery.6
Red blood cell transfusion is essential in
some cardiac surgical patients for the man-
agement of life-threatening haemorrhage. In
most cases, however, decisions to transfuse
are made because the haemoglobin (Hb)
concentration has fallen to a level or thresh-
old at which the surgeon or critical care
anaesthetist responsible for a patient’s care
feels uncomfortable.2 7 8 The transfusion
Strengths and limitations of this study
▪ The cost-effectiveness analysis was based on
data collected for a large randomised controlled
trial, the Transfusion Indication Threshold
Reduction trial, which randomised four times
more participants than the next largest trial com-
paring restrictive and liberal transfusion thresh-
olds after cardiac surgery.
▪ Very detailed individual patient cost and
quality-of-life data were collected from the trial
which achieved a high level of completeness of
follow-up.
▪ Only participants who breached the liberal
threshold were randomised; this avoided diluting
the treatment effect with similar numbers of par-
ticipants in each group who were unlikely to be
transfused.
▪ The unit costs of administering red blood cells
used in this study captured the nursing costs
associated with transfusion, but not other inputs
such as those of the transfusion laboratory.
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threshold varies between different cardiac surgery units
across the UK and between different doctors, which con-
tributes to the wide variation in blood usage observed in
cardiac surgical units (25–95%).4 5 9 A key reason for
the threshold variation is the lack of evidence regarding
what constitutes a ‘safe’ level of anaemia following
cardiac surgery.
The Transfusion Indication Threshold Reduction
(TITRe2) trial was designed to test the hypothesis that a
restrictive threshold for red blood cell transfusion (Hb
<7.5 g/dL) after cardiac surgery would reduce post-
operative morbidity and health service costs compared
to a liberal threshold (Hb <9 g/dL). The primary clin-
ical outcome for TITRe2 was a composite of a serious
infectious or ischaemic event within 3 months of ran-
domisation. The trial results reported no difference in
the primary clinical outcome between the transfusion
groups (the primary outcome was observed in 35.1%
and 33.0% of participants in the restrictive and liberal
groups, respectively). This ﬁnding supports the use of
either transfusion threshold as evaluated in the trial.
This might suggest a restrictive threshold is preferred
since this reduces unnecessary transfusions. However,
analyses of a secondary outcome, mortality at 90 days,
found a borderline signiﬁcant difference between the
groups (4.2% of patients in the restrictive group died vs
2.6% of patients in the liberal group, p=0.045) creating
uncertainty about recommending restrictive transfusion
after cardiac surgery.
Given the pressures on healthcare resources and the
costs and scarcity of red blood cells, it is important to
consider the cost-effectiveness as well as the clinical
effectiveness of alternative transfusion thresholds. We
are unaware of any previous trial-based economic evalu-
ation assessing the cost-effectiveness of alternative trans-
fusion thresholds after cardiac surgery. This paper
reports the methods and results of the within-trial cost-
effectiveness analysis for the TITRe2 trial.
METHODS
Our economic evaluation was based on the TITRe2
trial (ISRCTN70923932) which provided highly detailed
data on resource use and health-related quality of
life (HRQoL) of participants. The trial methods and
results are reported in detail elsewhere,7 10 and the
trial CONSORT diagram is provided in the online supple-
mentary appendix 1 of this paper. In summary, TITRe2
was a multicentre superiority trial in which patients aged
>16 years having non-emergency cardiac surgery, whose
Hb dropped to <9 g/dL during the postoperative hospital
stay, were randomised to a restrictive threshold (transfuse
if Hb <7.5 g/dL) or a liberal threshold (transfuse if
Hb<9 g/dL). Patients were recruited from 17 specialist
cardiac surgery centres in UK National Health Service
(NHS) hospitals between July 2009 and February 2013.
Our analysis was conducted from an NHS and per-
sonal social services perspective, as recommended by the
UK National Institute for Health and Care Excellence.11
The economic evaluation comprised a within-trial cost-
effectiveness analysis, with the main outcome measure
being quality-adjusted life years (QALYs), and took a
3-month time horizon, as we anticipated that most major
resource use would occur within 3 months of cardiac
surgery. Surgery was chosen as the time origin for our
analyses (rather than the point of randomisation, as was
the case with the analysis of effectiveness), in order to
capture the resources that would be required for the
intervention from a decision-maker’s perspective, that is,
to include all relevant costs (and effects) involved in
delivering the cardiac surgery.
Resource use and costs
Resource use data were collected on all signiﬁcant
health service resource inputs for the trial participants
up to the point of the 3 month follow-up. During the
index hospital admission, data collection was integrated
into the trial case report forms; data were collected on
blood products transfused, inpatient days by ward type,
type of cardiac surgery and reoperations, medications
and complications. At 3 months postoperatively, a
bespoke resource use questionnaire was used to obtain
estimates of healthcare resources used since hospital dis-
charge, for example, readmissions to hospital and
further contact with health professionals in primary or
secondary care. The costs of unrelated care post-
discharge were excluded. For example, our analysis
included the cost of readmissions for hypertension and
angina, but excluded the cost of readmissions for treat-
ment of cancer.
Unit costs used to value hospital and community
healthcare resource use were largely obtained from
national sources, for example, NHS Blood and
Transplant (NHSBT) price lists for blood products, the
National Schedule of Reference Costs for intensive care,
high-dependency and cardiac ward costs, MRI and CT
scans and many complications, and Unit Costs of
Health and Social Care for community costs.12–14 All
unit costs are provided in the online supplementary
appendix 2. Resources were valued in 2012/2013
pounds sterling; any unit costs in pre-2012/2013 prices
were inﬂated to 2012/2013 using the Hospital and
Community Health Services inﬂation index.14 Costs of
drugs given in hospital were taken from the Electronic
Marketing Information Tool where possible, which pro-
vides the reduced prices paid for generic drugs in hos-
pital.15 Drug costs not available from this source or
prescribed in the community were taken from the
British National Formulary.16
HRQoL and QALYs
The main outcome measure for the economic evalu-
ation was HRQoL, using QALYs, which were derived
from EQ-5D-3L utilities (measured on a continuous
scale and time under observation). The EQ-5D was
administered to participants preoperatively, and at
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6 weeks and 3 months postoperatively. The analysis of
QALYs required baseline utility to be modelled as a cov-
ariate; the correlation between baseline and 3-month
EQ-5D-3L utilities was assumed to be ≥0.3. Respondents
were assigned valuations derived from published UK
population tariffs.17 The number of QALYs accrued by
each participant was calculated assuming that a partici-
pant’s utility changed linearly between each of the time
points. For participants who died during the trial, their
utility was assumed to change linearly between the pre-
ceding time point and the time of death, and a value of
zero was given to participants from time of death
onwards.
Statistical methods
Our base-case analysis included all participants rando-
mised into the trial except those randomised in error
and those who withdrew consent for their data to be
used, which is consistent with the main effectiveness ana-
lyses. Analyses were performed on an intention-to-treat
basis. Overall, 2.5% of resource use data were completely
missing, and 10.7% of EQ-5D scores were missing across
the three time points in the trial. Missing resource use
and EQ-5D data were imputed by multiple imputation
using a series of chained regression equations.18 Five
values were predicted for each missing data cell, and a
method called Rubin’s Rule was used to summarise data
across the ﬁve data sets.19 Where resource use data were
partially missing, for example, for linked questions
where only the ﬁrst part was answered, mean imputation
was used. For example, if a participant reported general
practitioner visits, but did not record the number of
visits, the mean number of visits from other participants
was assigned to participants whose data were missing.
Given that baseline utility directly contributes to QALY
calculations, it is important to control for any potential
imbalances in baseline utility in the estimation of the
mean difference in QALYs between treatment groups, to
avoid introducing bias.20 QALYs were therefore adjusted
for baseline EQ-5D. Costs and effects were not dis-
counted as the time horizon was <12 months. The incre-
mental cost-effectiveness ratio (ICER) was derived from
the average costs and QALYs gained in each trial group,
producing an incremental cost per QALY gained by
implementing a restrictive threshold in place of a liberal
threshold. Non-parametric bootstrapping of costs and
QALYs was then used to quantify the degree of uncer-
tainty around the ICER. A 1000 bootstrap samples were
drawn for each of the ﬁve imputed data sets.21
Presentation of results
The mean costs and QALYs gained in each trial arm,
with SEs and 95% CIs are presented, as well as the
ICER. Uncertainty around the ICER is represented
graphically on the cost-effectiveness plane by the boot-
strap replicates of the mean difference in costs and
QALYs between the groups. The restrictive threshold
would be considered cost-effective if the ICER falls
below £20 000 per QALY, the level below which the
National Institute for Health and Care Excellence gener-
ally recommends interventions to the NHS; however, the
ICERs presented allow decision-makers to assess cost-
effectiveness at a willingness-to-pay threshold of their
choice.
Sensitivity analyses
Deterministic sensitivity analyses were used to investigate
the impact on the results of the cost and cost-
effectiveness analyses when varying key parameters one
at a time, or major cost drivers, such as treating costly
complications, and also to investigate the impact of
uncertainty on the cost-effectiveness results. In terms of
costs, key unit costs were varied, the costing was under-
taken from the point of randomisation rather than the
point of surgery, and the impact of high-cost participants
(outliers) were investigated. In terms of outcomes,
assumptions for calculating QALYs were varied, and life-
years gained was considered as an alternative outcome
measure to QALYs.
Subgroup analyses
Clinical opinion suggests that transfusion decisions
should be inﬂuenced by patients’ characteristics, and
that ‘at-risk’ patients should be transfused at a different
threshold. Subgroup analyses were conducted to investi-
gate whether cost-effectiveness results varied between
the prespeciﬁed participant subgroups used for the
effectiveness analyses:
▸ Operation type (isolated coronary artery bypass graft-
ing (CABG) vs other operation types);
▸ Age at operation (<75 vs ≥75 years);
▸ Preoperative diagnosis of diabetes (none vs diet, oral
medication or insulin controlled);
▸ Preoperative diagnosis of lung disease (none vs
chronic pulmonary disease or asthma);
▸ Preoperative renal impairment (estimated glomerular
ﬁltration rate ≤60 mL/min vs estimated glomerular
ﬁltration rate >60 mL/min);
▸ Sex (males vs females);
▸ Preoperative ventricular function (good vs moderate
or poor).
The impact of subgroups was evaluated using ordinary
least squares regression separately for total costs and for
QALYs, conditional on treatment group, subgroup and
an interaction between treatment group and subgroup,
(and baseline EQ-5D for QALYs only).
RESULTS
The trial randomised a total of 2007 participants; four
withdrew, leaving an analysis population consisting of
2003 participants, 1000 in the restrictive group and 1003
in the liberal group. Participants had a mean age of
69 years, and 69% were men. Most participants under-
went coronary artery bypass grafting (40.7%) or valve
surgery (30.5%).10
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Resource use and costs
There was little difference in resource use between the
groups (table 1). Red blood cells were the only resource
item for which there was a clear difference, an expected
ﬁnding given that the liberal group by deﬁnition had
more red blood cells transfused (mean difference 1.00
(SE 0.14) unit per participant). A detailed list of all the
unit cost values attached to these resources is provided
in the online supplementary appendix 2.
A breakdown of total costs of care from surgery to
3 months is shown in table 2. Key drivers of total costs
were surgery, complications and length of stay (LOS).
The difference in the mean units of red blood cells
transfused translated into a statistically signiﬁcant
average difference in red blood cell costs (£140, SE 19,
p<0.0001). The differences in other cost components
between the groups were small, although there was sub-
stantial uncertainty around these differences (as is
evident from the large SEs). Total costs were £17 945
(SE 332) in the restrictive group and £18 127 (SE 357)
in the liberal group, resulting in a mean difference
between the groups of −£182 (SE 488; table 2). This dif-
ference in cost was largely associated with the higher
cost of red blood cells in the liberal group.
HRQoL and QALYs
There was very little difference in EQ-5D scores between
the trial groups at any of the three time points (table 3).
On average, participants’ EQ-5D scores did not quite
return to their preoperative level by 3 months in either
treatment group. QALYs to 3 months were 0.180 for
both the restrictive and liberal groups, with a mean dif-
ference of only 0.0004 (SE 0.0021; table 3). This differ-
ence of 0.0004 QALYs is ∼3.5 quality-adjusted hours.
Although there was a signiﬁcant difference in deaths
between the groups in favour of the liberal group, this
did not translate into a difference in QALYs between the
groups. Exploratory plots of the QALY data for survivors
and non-survivors at 3 months revealed that it was not
just participants who died who had low QALYs, but also
many other participants, hence the difference in deaths
did not have a major impact on the quality-of-life results.
Cost-effectiveness
When we considered the point estimate (the initial
mean estimate), the restrictive threshold is considered
cost-effective: the restrictive threshold is dominant over
the liberal threshold, since it is both more effective and
less costly (table 4). However, there is great uncertainty
around this result, as shown on the cost-effectiveness
plane in ﬁgure 1. The differences in costs and QALYs
between the groups are incredibly small, and therefore
the point estimate (the black dot) is close to the origin.
The bootstrap replicates of the cost and QALY differ-
ences cover all four quadrants of the cost-effectiveness
plane, which illustrates that there is actually very little
difference between the two groups along with much
uncertainty. There is a 43% probability that the
restrictive threshold dominates the liberal threshold, but
also a 20% probability of the reverse scenario, that the
liberal threshold dominates the restrictive threshold. In
reality, there is no difference in QALYs between the
groups, the 95% CI suggests the maximum difference is
less than ± 2 days.
Sensitivity analyses
Sensitivity analyses (see online supplementary appendix 3)
demonstrated that the conclusions were sensitive to a few
very high-cost participants, but robust to changes in unit
costs, to moving the time origin from surgery to the time
of randomisation, to alternative assumptions for calculat-
ing QALYs, and to using life-years instead of QALYs as an
alternative outcome measure.
The distribution of total costs per participant was posi-
tively skewed for both groups. This skewness was
enhanced by the existence of a few very high-cost out-
liers, especially in the liberal group. Four participants,
all in the liberal group, had costs over £100 000
(£101 173; £107 163; £108 865 and £144 985, compared
to the average costs of £18 127). These participants did
not have unexpected events; rather, they had large
numbers of expected complications and stayed in hos-
pital with a high level of care for some time. Therefore,
there were no grounds for excluding these participants
from our analyses. Nevertheless, it is instructive to inves-
tigate the impact they are having on results since the
imbalance across groups of these outliers could easily
have arisen by chance. If the participant with the
highest cost is excluded, the difference in costs between
the groups reduces from −£182 to −£55 (smaller than
the cost of the average difference in red blood cell use).
If participants with the four highest costs are excluded,
the liberal group becomes less expensive than the
restrictive group, and the difference in costs between
the groups changes from −£182 to +£208. It is clear that
these four participants exerted a signiﬁcant impact on
the average costs of participants in the liberal group.
Subgroup analyses
There was evidence of only one subgroup effect: partici-
pants in the restrictive group with chronic pulmonary
disease or asthma had slightly less QALYs compared to
other participants (p=0.003). See online supplementary
appendix 4 for more details.
DISCUSSION
There was very little difference between the alternative
transfusion groups in either costs or effects, and great
uncertainty around the cost-effectiveness results. When a
breakdown of total costs was considered, there was a
clear difference in the costs associated with red blood
cells between the two groups as expected, because the
liberal group was given more red blood cells by deﬁn-
ition; otherwise, cost components were very similar. The
differences in costs between groups were about the same
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Table 1 Resource use per participant to 3 months from surgery
Resource use component
Randomised to restrictive
threshold (N=1000)
Frequency (%)
or mean (SE)
Randomised to liberal
threshold (N=1003)
Frequency (%)
or mean (SE)
Restrictive vs
liberal threshold
% or mean (SE)
difference
Red blood cells—number of units/participant 2.08 (0.09) 3.07 (0.11) −1.00 (0.14)
Type of cardiac procedure—number (%) of participants
Coronary artery bypass grafting 408 (41) 408 (41) 0
Valve 307 (31) 304 (30) 1
Coronary artery bypass grafting and valve 195 (20) 203 (20) 0
Other 90 (9) 88 (9) 0
Blood products—number of units/participant
Fresh frozen plasma 1.00 (0.06) 0.95 (0.06) 0.05 (0.08)
Platelets 0.65 (0.03) 0.64 (0.03) 0.01 (0.05)
Cryoprecipitate 0.23 (0.03) 0.21 (0.02) 0.02 (0.04)
Inpatient complications
Primary outcome—number (%) of participants
Antibiotics for infectious complication 341 (34) 344 (34) 0
Stroke 14 (1) 16 (2) −1
Suspected myocardial infarction 3 (0) 7 (1) −1
Gut infarction 5 (1) 1 (0) 1
Acute kidney injury—stage 3 60 (6) 51 (5) 1
Other complications—number of events/participant
Reoperation 0.09 (0.01) 0.10 (0.01) −0.01 (0.02)
Reintubation 0.07 (0.01) 0.07 (0.01) 0.00 (0.01)
Tracheostomy 0.03 (0.01) 0.03 (0.01) 0.00 (0.01)
Mask continuous positive airway pressure 0.13 (0.01) 0.12 (0.01) 0.01 (0.02)
Pneumothorax requiring chest drainage 0.01 (0.00) 0.01 (0.00) 0.00 (0.01)
Pleural effusion requiring drainage 0.06 (0.01) 0.06 (0.01) 0.00 (0.01)
Pacing 0.31 (0.02) 0.31 (0.02) 0.00 (0.02)
SVT/AF requiring treatment 0.41 (0.02) 0.39 (0.02) 0.02 (0.03)
VF/VT requiring intervention 0.02 (0.01) 0.01 (0.00) 0.01 (0.01)
Low cardiac output 0.11 (0.01) 0.11 (0.01) 0.00 (0.01)
Inpatient length of stay—days/participant
Cardiac intensive care unit (CICU) 1.14 (0.12) 1.12 (0.13) 0.02 (0.18)
High dependency unit (HDU) 3.09 (0.12) 3.05 (0.12) 0.04 (0.17)
Ward 5.67 (0.15) 5.83 (0.17) −0.17 (0.23)
Another unit / hospital 1.27 (0.20) 1.36 (0.19) −0.09 (0.27)
Blood saving techniques—number (%) of participants
Tranexamic acid 807 (81) 810 (81) 0
Trasylol 41 (4) 35 (3) 1
Intraoperative cell salvage 482 (48) 503 (50) −2
Postoperative cell salvage 56 (6) 46 (5) 1
Fluids in theatre/CICU/HDU—number (%) of participants
Inotropes 624 (62) 614 (61) 1
Gelofusine 843 (84) 836 (83) 1
Hydroxyethyl starch (HES) 231 (23) 233 (23) 0
Readmissions to hospital
Length of stay—days/participant 1.38 (0.15) 1.46 (0.16) −0.08 (0.22)
Accident and Emergency (A&E) attendances
Total A&E visits—number/participant 0.09 (0.01) 0.08 (0.01) 0.01 (0.01)
Outpatient appointments—number/participant
Cardiac surgery outpatient visits 0.44 (0.02) 0.51 (0.02) −0.07 (0.03)
Cardiology outpatient visits 0.28 (0.02) 0.26 (0.02) 0.03 (0.03)
Other outpatient visits 0.17 (0.02) 0.17 (0.02) 0.00 (0.03)
Continued
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Table 3 Results for EQ-5D scores and QALYs
Randomised to restrictive
threshold (N=1000)
Mean (SE)
Randomised to liberal
threshold (N=1003)
Mean (SE)
Restrictive vs liberal
threshold
Mean difference (SE)
EQ-5D time point*
Baseline 0.765 (0.008) 0.767 (0.007) −0.001 (0.011)
6 weeks 0.692 (0.008) 0.686 (0.008) 0.006 (0.011)
3 months 0.748 (0.009) 0.750 (0.008) −0.002 (0.012)
QALYs to 3 months (adjusted
for baseline EQ-5D)
0.1802 (0.0015) 0.1798 (0.0016) 0.0004 (0.0021)
*Deaths included as zero.
QALY, quality-adjusted life year.
Table 1 Continued
Resource use component
Randomised to restrictive
threshold (N=1000)
Frequency (%)
or mean (SE)
Randomised to liberal
threshold (N=1003)
Frequency (%)
or mean (SE)
Restrictive vs
liberal threshold
% or mean (SE)
difference
Other healthcare contacts—number/participant
General practitioner at surgery 1.99 (0.06) 2.07 (0.07) −0.09 (0.10)
General practitioner at home 0.43 (0.04) 0.37 (0.03) 0.06 (0.06)
Practice nurse 1.56 (0.13) 1.57 (0.14) −0.01 (0.19)
District nurse 2.47 (0.20) 2.21 (0.23) 0.26 (0.30)
SVT/AF, supraventricular tachycardia/atrial fibrillation; VF/VT, ventricular fibrillation/ventricular tachycardia.
Table 2 Breakdown of total average cost per participant for both trial groups
Cost component
Randomised to restrictive
threshold (N=1000)
Mean cost (£) (SE)
Randomised to liberal
threshold (N=1003)
Mean cost (£) (SE)
Restrictive vs liberal
threshold
Mean cost (£)
difference (SE)
Red blood cells 287 (13) 427 (15) −140 (19)
Hospital inpatient episode
Initial cardiac surgery 7309 (18) 7313 (18) −4 (26)
Other blood products 206 (12) 199 (11) 7 (16)
Complications and serious
adverse events
2684 (137) 2714 (146) −30 (200)
Length of hospital stay* 5854 (201) 5892 (221) −38 (299)
Blood saving techniques 159 (9) 152 (8) 7 (12)
Regular medications 26 (2) 29 (2) −3 (3)
Fluids 55 (1) 55 (1) 0 (2)
Total 16 293 (309) 16 353 (339) −60 (459)
Postdischarge
Hospital readmissions 770 (85) 753 (78) 17 (116)
Accident and Emergency
visits
16 (2) 12 (2) 4 (3)
Outpatient appointments 202 (6) 216 (7) −14 (9)
Other medical/social care 378 (14) 366 (16) 12 (21)
Total 1365 (90) 1347 (82) 18 (122)
Total costs 17 945 (332) 18 127 (357) −182 (488)
*Includes days in another unit/hospital once transferred out of the cardiac unit.
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when considering only the red blood cell costs and
when considering all costs; however, the former differ-
ence was estimated more precisely than the latter. Mean
QALYs to 3 months were effectively identical in both
groups. The point estimate of cost-effectiveness sug-
gested that the restrictive group was more effective (very
slightly greater QALY gain) and less costly than the
liberal group (ie, dominant), and therefore cost-
effective. However, the extreme uncertainty around this
result makes the point estimate less informative. The
uncertainty is shown on the cost-effectiveness plane by
the position of the point estimate close to the origin,
and by the fact that the bootstrap replicates of the cost
and QALY differences covered all four quadrants of the
plane. Moreover, there were several outliers in the
liberal group which exerted a substantial inﬂuence on
the average costs of participants in that treatment group,
reversing the direction of the results described above
when they were excluded.
Our economic evaluation had several key strengths. It
was based on high-quality cost and quality of life individual
patient data collected in a randomised trial. Very detailed
data collection was undertaken, and the trial achieved
excellent completeness of follow-up (follow-up at
3 months postrandomisation was obtained for 98.7% of
participants). TITRe2 was a large trial, randomising four
times more participants than the next largest trial compar-
ing restrictive and liberal transfusion thresholds after
cardiac surgery. In TITRe2, only participants who brea-
ched the liberal threshold were randomised; this avoided
diluting the treatment effect with similar numbers of parti-
cipants in each group who were unlikely to be transfused.
Costs and cost-effectiveness estimates were similarly not
diluted by patients who were unlikely to be transfused.
There is one limitation to note around the unit costs of
administering blood products. The unit costs of adminis-
tering red blood cells used in this study captured the
nursing costs associated with transfusion (based on UK
data), but not other inputs such as those of the transfusion
laboratory; and no costs associated with administration
were included for other blood products. Unit costs for
blood administration used here were much lower than
those reported elsewhere.23–25 Given there was only a dif-
ference of one unit of red blood cells between the transfu-
sion groups, (and a very small difference in total costs), it
is unlikely that the inclusion of additional blood adminis-
tration costs would alter the conclusions.
To the best of our knowledge, this is the ﬁrst
trial-based economic evaluation assessing the cost-
effectiveness of alternative transfusion thresholds after
cardiac surgery. A Cochrane systematic review of rando-
mised controlled trials (RCTs) comparing restrictive and
liberal transfusion thresholds in surgical patients and
the critically ill was published in 2012.26 None of the
RCTs included in the review, nor ﬁve additional trials
published subsequently, included an integral economic
evaluation,27–31 (one pilot trial included an exploratory
economic evaluation, but the only inpatient resource
captured was LOS by level of care).31
Although the TITRe2 trial was a well-designed and
rigorously conducted trial, the interpretation of its cost-
effectiveness results is challenging because the differ-
ences in costs and quality of life between the groups
were small or uncertain (across both the clinical and
Table 4 Base case cost-effectiveness results
Total costs (95% CI) QALYs (95% CI) ICER
Probability restrictive is
cost-effective at a ceiling
ratio of
Restrictive
threshold
(N=1000)
Liberal
threshold
(N=1003)
Restrictive
vs liberal
threshold
Restrictive
threshold
(N=1000)
Liberal
threshold
(N=1003)
Restrictive
vs liberal
threshold Cost/QALY £20 000 £50 000 £100 000
£17 945
(£17 273 to
£18 618)
£18 127
(£17 450
to
£18 804)
−£182
(−£1108
to £744)
0.1802
(0.1772 to
0.1832)
0.1798
(0.1766 to
0.1829)
0.0004
(−0.0037 to
0.0045)
Restrictive
dominant
(−£428
064)
65% 66% 66%
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
95% CIs are based on parametric methods, using SEs from the bootstrap replicates and a t distribution with degrees of freedom v=(M−1)
(1+r−1)2, where r is the ratio of the between-imputation component of the variance and the within-imputation component of the variance, and M
is the number of imputed data sets.22
Figure 1 Cost-effectiveness plane. In order that the points
could be seen, only 1000 replicates were plotted (200
replicates for each of the five imputations).
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cost-effectiveness analyses). Point estimates of cost-
effectiveness (based on QALYs as the primary health
economic outcome measure or life years in a sensitivity
analysis) suggested that a restrictive threshold was cost-
effective, but there was extreme uncertainty around
these results. From an economic perspective, we con-
clude that there is no difference between the restrictive
and liberal groups. While there was no difference in the
primary clinical outcome, there was a borderline differ-
ence in mortality between the groups, favouring a liberal
threshold. It is difﬁcult to recommend restrictive transfu-
sion after cardiac surgery, given that more patients died
in the restrictive group. While there is a growing body of
evidence that restrictive transfusion thresholds are safe
for most patient groups,32 there is recognition that
patients with acute or chronic cardiovascular disease,
may beneﬁt from more liberal transfusion.33 34
A difference of ∼£200 between the groups is a modest
cost difference (∼1% of total costs). However, since 34 174
cardiac surgery procedures were undertaken in the UK in
2012/2013,35 a difference of £200 in each procedure
would have resulted in savings or additional costs of £6.8
million for the NHS. The effect of this cost difference, and
whether it is a cost saving or additional cost, is clearly
important for the NHS. If there is a saving of ∼£200 per
patient, and this is largely attributable to savings in the cost
of blood, this would substantially reduce the amount paid
to NHSBT for blood products. These savings could be
used to support Patient Blood Management (PBM) initia-
tives, to optimise care for patients who might need a trans-
fusion. A recent audit of PBM in surgery highlighted
considerable variation in practice, and the need for hospi-
tals to develop single-unit transfusion policies with clearly
deﬁned transfusion triggers.36
In summary, our ﬁndings suggest that there is no
health economic evidence to suggest a difference
between the two alternative blood transfusion thresh-
olds, as there was very little difference between the alter-
native transfusion groups in either costs or effects, but
great uncertainty around the cost-effectiveness results.
Author affiliations
1Nuffield Department of Population Health, Health Economics Research
Centre, University of Oxford, Oxford, UK
2Eli Lilly and Company Limited, Lilly House, Basingstoke, Hampshire, UK
3Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of
Bristol, Bristol, UK
4Bristol Heart Institute, School of Clinical Sciences, University of Bristol,
Bristol, UK
5Department of Cardiovascular Sciences and NIHR Leicester Biomedical
Research Unit in Cardiovascular Medicine, University of Leicester, Leicester,
UK
Acknowledgements The authors thank all the patients who took part in the
TITRe2 trial, and all the nurses and clinicians in the trial centres who helped
to collect data on costs and patient outcomes which were used in the
cost-effectiveness analysis.
Collaborators Transfusion Indication Threshold Reduction study investigators
and trial sites. Blackpool Victoria Hospital and Lancaster University. Investigators:
Mr Augustine Tang and Dr Palaniappan Saravanan. Research team: Charlotte
Waterhouse. Royal Sussex County Hospital, Brighton. Investigator: Dr Robert
Kong. Research team: Nicola Skipper. University Hospitals NHS Foundation
Trust, Bristol. Investigator: Professor Gavin Murphy (until August 2012)/
Professor Gianni Angelini (from August 2012). Research team: Emma Hopkins
and Penny Lambert. University Hospital Coventry and Warwickshire NHS Trust,
Coventry. Investigator: Mr Sunil K Bhudia. Research team: Denise Gocher. Castle
Hill Hospital, Hull. Investigator: Dr Sean Bennett. Research team: Neil Smith and
Adam Walker. Derriford Hospital, Plymouth. Investigators: Dr Mark Bennett and
Mr Malcolm Dalrymple-Hay. Research team: Maxine Pearse. Essex
Cardiothoracic Centre, Basildon. Investigator: Professor Andrew J Ritchie.
Research team: Emily Redman and Amanda Solesbury. Royal Infirmary of
Edinburgh, Edinburgh. Investigator: Mr Vipin Zamvar. Hammersmith Hospital,
London. Investigator: Dr Geoffrey Lockwood. Research team: Dr Francesca
Fiorentino and Alima Rahman. King’s College Hospital NHS Foundation Trust.
Investigator: Dr Gudrun Kunst. Research team: Georgina Parsons and Fiona
Wade-Smith. The Leeds Teaching Hospitals NHS Trust. Investigator: Dr Michael
H Cross. Research team: Stuart Elliot and Zoe Beardow. Glenfield Hospital,
Leicester. Investigator: Professor Tom Sypt. Research team: Martina Williams.
Liverpool Heart and Chest Hospital Foundation Trust. Investigator: Mr Brian Fabri
(until December 2012)/Mr Mark Field (from January 2013). Research team: Ian
Kemp and Andrea Young. The James Cook University Hospital, Middlesbrough.
Investigator: Dr Nick Stratford. Research team: Heather Robinson. Freeman
Hospital, Newcastle. Investigator: Mr Stephen Clark. Research team: Sarah
Rowling and Hazel Forsyth. University Hospital Southampton Foundation Trust.
Investigator: Dr Ravi Gill. Research team: Beverley Wadhams and Kim de
Courcy-Golder. New Cross Hospital, Wolverhampton. Investigator: Dr Ian
Morgan. Research team: Emma Greatbach and Alex Ng.
Contributors GJM, BCR, GDA and CAR conceived the trial. GJM, BCR, GDA,
CAR and SW wrote the application for funding to conduct the trial. GJM,
BCR, GDA and CAR designed the trial. KP, BCR and CAR designed the trial
data set and collected the outcome data which were used for the economic
evaluation. EAS and SW conceived and designed the health economic
evaluation. EAS conducted the economic analysis with help from SW and DB.
EAS and SW drafted the paper. All authors participated in writing the paper,
reviewed it for important intellectual content and approved the final version.
Funding This project was funded by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) Programme (ref: 06/402/94).
BCR and the research nurse team in Bristol were supported, in part, by the
NIHR Bristol Biomedical Research Unit in Cardiovascular Disease, and GJM,
GDA and CAR were supported by the British Heart Foundation (ref: CH/12/1/
29419 and CH/92027). DB was working full-time at the Health Economics
Research Centre, University of Oxford at the time of the cost-effectiveness
work and moved to Eli Lilly at a later date. The study funder had no role in
the cost-effectiveness study design, data collection, data analysis, data
interpretation, or writing of the paper. EAS and SW had full access to all the
data in the study, and the authors had final responsibility for the decision to
submit for publication. The views and opinions expressed herein are those of
the authors and do not necessarily reflect those of the HTA programme, the
British Heart Foundation, NIHR, NHS or the Department of Health.
Competing interests RCMB, GJM (up to 31 Aug 2012), KP, SW, EAS, DB and
BCR had varying percentages of their salaries paid for by the grant awarded for
the trial. Some or all of the time contributed by GDA, GJM (from 1 Sep 2012)
and CAR was paid for by the British Heart Foundation. CAR is a member of the
NIHR Health Technology Assessment Commissioning Board, Systematic
Reviews Programme Advisory Board and the Efficient Studies Design Board.
Ethics approval The trial was approved by a UK NHS Research Ethics
Committee (reference number 08/H0606/125) and conducted in accordance with
the principles of the International Conference on Harmonisation of Good Clinical
Practice under the oversight of the study sponsor (University of Bristol).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Extra data on the costing information used for our
analysis will be available by emailing sarah.wordsworth@dph.ox.ac.uk. Data
will not be made available for sharing until after publication of the main
Health Technology Assessment Report and the cost-effectiveness analysis
paper. Thereafter, anonymised individual participant data may be made
available for secondary research, conditional on assurance from the
secondary researcher that the proposed use of the data is compliant with the
8 Stokes EA, et al. BMJ Open 2016;6:e011311. doi:10.1136/bmjopen-2016-011311
Open Access
group.bmj.com on October 27, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
MRC Policy on Data Preservation and Sharing regarding scientific quality,
ethical requirements and value for money. A minimum requirement with
respect to scientific quality will be a publicly available prespecified protocol
describing the purpose, methods and analysis of the secondary research, for
example, a protocol for a Cochrane systematic review.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Habib RH, Zacharias A, Schwann TA, et al. Role of hemodilutional
anemia and transfusion during cardiopulmonary bypass in renal
injury after coronary revascularization: implications on operative
outcome. Crit Care Med 2005;33:1749–56.
2. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality,
postoperative morbidity, and cost after red blood cell transfusion in
patients having cardiac surgery. Circulation 2007;116:2544–52.
3. Karkouti K, Wijeysundera DN, Beattie WS, et al. Risk associated
with preoperative anemia in cardiac surgery: a multicenter cohort
study. Circulation 2008;117:478–84.
4. Bennett-Guerrero E, Zhao Y, O’Brien SM, et al. Variation in use of
blood transfusion in coronary artery bypass graft surgery. JAMA
2010;304:1568–75.
5. Murphy MF, Murphy GJ, Gill R, et al. National Comparative Audit of
Blood Transfusion: 2011 Audit of Blood Transfusion in Adult Cardiac
Surgery. 2013. http://hospital.blood.co.uk/media/26859/nca-2011_use_
of_blood_in_adult_cardiac_surgery_report.pdf (accessed 30 Jul 2015).
6. Wells AW, Llewelyn CA, Casbard A, et al. The EASTR Study:
indications for transfusion and estimates of transfusion recipient
numbers in hospitals supplied by The National Blood Service.
Transfus Med 2009;19:315–28.
7. Brierley RCM, Pike K, Miles A, et al. A multi-centre randomised
controlled trial of Transfusion Indication Threshold Reduction on
transfusion rates, morbidity and healthcare resource use following
cardiac surgery: study protocol. Transfus Apher Sci 2014;50:451–61.
8. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU.
Is there a reason? Chest 1995;108:767–71.
9. Stover EP, Siegel LC, Parks R, et al. Variability in transfusion
practice for coronary artery bypass surgery persists despite national
consensus guidelines: a 24-institution study. Institutions of the
Multicenter Study of Perioperative Ischemia Research Group.
Anesthesiology 1998;88:327–33.
10. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive
transfusion after cardiac surgery. N Engl J Med 2015;372:
997–1008.
11. National Institute for Health and Care Excellence. Guide to the
Methods of Technology Appraisal 2013. 2013. https://www.nice.org.
uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-
technology-appraisal-2013-pdf (accessed 30 Jul 2015).
12. Department of Health. National Schedule of Reference Costs 2012–
13. London: Department of Health, 2013.
13. NHS Blood and Transplant. NHS Blood and Transplant Price List
2012–2013. 2012. http://hospital.blood.co.uk/products/ (accessed 28
Sep 2012).
14. Curtis L. Unit costs of health and social care 2013. Canterbury:
Personal Social Services Research Unit, University of Kent, 2013.
15. Department of Health Commercial Medicines Unit. Electronic
Marketing Information Tool (eMIT). Drugs and Pharmaceutical
Electronic Market Information (eMit). http://cmu.dh.gov.uk/
electronic-market-information-tool-emit/ (accessed 10 Feb 2014).
16. Joint Formulary Committee. British national formulary. No. 66.
London: BMJ Group and Pharmaceutical Press, 2013.
17. Dolan P, Gudex C, Kind P, et al. A social tariff for euroqol: results
from a UK general population survey. University of York, 1995.
18. White IR, Royston P, Wood AM. Multiple imputation using chained
equations: issues and guidance for practice. Stat Med
2011;30:377–99.
19. Rubin DB. Multiple Imputation for non-response in surveys.
New York: John Wiley, 1987.
20. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in
trial-based cost-effectiveness analysis: the importance of controlling
for baseline utility. Health Econ 2005;14:487–96.
21. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness
analysis up by its bootstraps: a non-parametric approach to
confidence interval estimation. Health Econ 1997;6:327–40.
22. Briggs A, Clark T, Wolstenholme J, et al. Missing…presumed at
random: cost-analysis of incomplete data. Health Econ
2003;12:377–92.
23. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of
blood transfusions in surgical patients at four hospitals. Transfusion
2010;50:753–65.
24. Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma
transfusions in medical and surgical inpatients at a US hospital. Vox
Sang 2016;111:55–61.
25. Abraham I, Sun D. The cost of blood transfusion in Western
Europe as estimated from six studies. Transfusion 2012;52:1983–8.
26. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and
other strategies for guiding allogeneic red blood cell transfusion.
Cochrane Database Syst Rev 2012;(4):CD002042.
27. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive
transfusion in high-risk patients after hip surgery. N Engl J Med
2011;365:2453–62.
28. Shehata N, Burns LA, Nathan H, et al. A randomized controlled pilot
study of adherence to transfusion strategies in cardiac surgery.
Transfusion 2012;52:91–9.
29. Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive
transfusion thresholds for patients with symptomatic coronary artery
disease. Am Heart J 2013;165:964–71.e1.
30. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies
for acute upper gastrointestinal bleeding. N Engl J Med
2013;368:11–21.
31. Walsh TS, Boyd JA, Watson D, et al. Restrictive versus liberal
transfusion strategies for older mechanically ventilated critically ill
patients: a randomized pilot trial. Crit Care Med 2013;41:2354–63.
32. Holst LB, Petersen MW, Haase N, et al. Restrictive versus liberal
transfusion strategy for red blood cell transfusion: systematic review
of randomised trials with meta-analysis and trial sequential analysis.
BMJ 2015;350:h1354.
33. Docherty AB, O’Donnell R, Brunskill S, et al. Effect of restrictive
versus liberal transfusion strategies on outcomes in patients with
cardiovascular disease in a non-cardiac surgery setting: systematic
review and meta-analysis. BMJ 2016;352:i1351.
34. Patel NN, Avlonitis VS, Jones HE, et al. Indications for red blood cell
transfusion in cardiac surgery: a systematic review and
meta-analysis. Lancet Haematol 2015;2:e543–53.
35. The Society for Cardiothoracic Surgery in Great Britain & Ireland.
Blue Book Online. 2013. http://bluebook.scts.org
36. NHS Blood and Transplant. 2015 Audit of Patient Blood
Management in adults undergoing elective, scheduled surgery.
2016. http://hospital.blood.co.uk/audits/national-comparative-audit/
(accessed 20 Apr 2016).
Stokes EA, et al. BMJ Open 2016;6:e011311. doi:10.1136/bmjopen-2016-011311 9
Open Access
group.bmj.com on October 27, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
randomised controlled trial
cardiac surgery? Findings from the TITRe2
more cost-effective than liberal levels after 
Are lower levels of red blood cell transfusion
G D Angelini, G J Murphy and B C Reeves
E A Stokes, S Wordsworth, D Bargo, K Pike, C A Rogers, R C M Brierley,
doi: 10.1136/bmjopen-2016-011311
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/8/e011311
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/8/e011311
This article cites 24 articles, 4 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (304)Surgery
 (278)Health economics
 (585)Evidence based practice
 (641)Cardiovascular medicine
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 27, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
